

ACTG 5403 (Participant Summary Sheet)

Giving standardized Estradiol Therapy In Transgender women to Research

Interactions with HIV Therapy: the GET IT RIgHT Study

Brief Description: Transgender women (TW) are the fastest-growing group of people with HIV (PWH). Historically, TW have had few opportunities to participate in research, and often experience barriers to engaging in care. More research is needed help providers when it comes to choosing HIV medications in TW on Feminizing Hormone Therapy (FHT).

Purpose of this Study: The purpose of this study is to determine the best combination of antiretroviral therapy for transgender women living with HIV who take feminization hormonal therapy. All participants will receive FHT. The study will determine if TW remain undetectable while receiving FHT for 48 weeks. Additionally, it will assess if hormone levels change based on the type of HIV medication taken.

Requirements to Enter Study:

- 18 years or older
- A person living with HIV taking certain ART medications with a viral load of less than 400 copies.
- Identify as a TW or as a female or transfeminine person with male sex assigned at birth
- Desire to initiate or restart FHT
- Ability and willingness to provide informed consent

Treatment: Oral 17- β -estradiol 2mg once daily. Dose may change based on desired goals and hormone levels. Oral 17- β -estradiol is provided by the study.

Duration of Study: The study will last 48 weeks (about 1 year).

For more information contact:

**Vanessa Sutton,
Clinical Research Nurse Practitioner,
Infectious Diseases Clinical Trials Unit, University of Colorado Anschutz
Medical Campus**

Phone: 303-724-0712

E-mail: Vanessa.Sutton @cuanschutz.edu